Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II, Multinational Clinical Study of NOX66 (Veyonda) in a Broad Spectrum of Solid Cancers Including Rare Cancers

Trial Profile

A Phase II, Multinational Clinical Study of NOX66 (Veyonda) in a Broad Spectrum of Solid Cancers Including Rare Cancers

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 02 May 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Idronoxil (Primary)
  • Indications Lung cancer; Prostate cancer; Solid tumours
  • Focus Therapeutic Use
  • Acronyms DARRT-2
  • Sponsors Noxopharm
  • Most Recent Events

    • 24 Apr 2023 According to a Noxopharm media release, the process to discontinue trial has commenced, with trial sites notified and final dosing dates for patients being determined. A safety follow-up period will occur after the last treatment as per regulatory requirements, and the company will continue to offer existing trial patients and their doctors the opportunity to access Veyonda via a tailored compassionate use program, pending FDA approval.
    • 24 Apr 2023 According to a Noxopharm media release, the company discontinued trial due to slow patient recruitment due to the ongoing COVID impact on the US healthcare system, as well as challenges with patients accepting the drug's suppository delivery method, led to a projected unsustainable rise in costs and trial delays.
    • 24 Apr 2023 Status changed from recruiting to discontinued, according to a Noxopharm media release.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top